View Item 

Show simple item record

Biological therapies in the systemic management of psoriasis: International Consensus Conference

dc.contributor.authorSterry, Wolframen_US
dc.contributor.authorBarker, J.en_US
dc.contributor.authorBoehncke, W. -H.en_US
dc.contributor.authorBos, J. D.en_US
dc.contributor.authorChimenti, S.en_US
dc.contributor.authorChristophers, Ennoen_US
dc.contributor.authorDe La Brassinne, M.en_US
dc.contributor.authorFerrandiz, C.en_US
dc.contributor.authorGriffiths, C.en_US
dc.contributor.authorKatsambas, A.en_US
dc.contributor.authorKragballe, K.en_US
dc.contributor.authorLynde, C.en_US
dc.contributor.authorMenter, Alanen_US
dc.contributor.authorOrtonne, J. -P.en_US
dc.contributor.authorPapp, K.en_US
dc.contributor.authorPrinz, J.en_US
dc.contributor.authorRzany, B.en_US
dc.contributor.authorRonnevig, J.en_US
dc.contributor.authorSaurat, J.-H.en_US
dc.contributor.authorStahle, M.en_US
dc.contributor.authorStengel, F. M.en_US
dc.contributor.authorVan De Kerkhof, P.en_US
dc.contributor.authorVoorhees, John J.en_US
dc.date.accessioned2010-06-01T19:40:52Z
dc.date.available2010-06-01T19:40:52Z
dc.date.issued2004-08en_US
dc.identifier.citationSterry, W.; Barker, J.; Boehncke, W.-H.; Bos, J.D.; Chimenti, S.; Christophers, E.; De La Brassinne, M.; Ferrandiz, C.; Griffiths, C.; Katsambas, A.; Kragballe, K.; Lynde, C.; Menter, A.; Ortonne, J.-P.; Papp, K.; Prinz, J.; Rzany, B.; Ronnevig, J.; Saurat, J.-H.; Stahle, M.; Stengel, F.M.; Van De Kerkhof, P.; Voorhees, J. (2004). "Biological therapies in the systemic management of psoriasis: International Consensus Conference." British Journal of Dermatology 151(s69): 3-17. <http://hdl.handle.net/2027.42/72815>en_US
dc.identifier.issn0007-0963en_US
dc.identifier.issn1365-2133en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72815
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15265063&dopt=citationen_US
dc.description.abstractPsoriasis is a chronic, immune-mediated disorder that usually requires long-term treatment for control. Approximately 25% of patients have moderate to severe disease and require phototherapy, systemic therapy or both. Despite the availability of numerous therapeutic options, the long-term management of psoriasis can be complicated by treatment-related limitations. With advances in molecular research and technology, several biological therapies are in various stages of development and approval for psoriasis. Biological therapies are designed to modulate key steps in the pathogenesis of psoriasis. Collectively, biologicals have been evaluated in thousands of patients with psoriasis and have demonstrated significant benefit with favourable safety and tolerability profiles. The limitations of current psoriasis therapies, the value of biological therapies for psoriasis, and guidance regarding the incorporation of biological therapies into clinical practice are discussed.en_US
dc.format.extent167309 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2004 British Association of Dermatologistsen_US
dc.subject.otherAlefacepten_US
dc.subject.otherBiologicalsen_US
dc.subject.otherEfalizumaben_US
dc.subject.otherEtanercepten_US
dc.subject.otherInfliximaben_US
dc.subject.otherPsoriasisen_US
dc.titleBiological therapies in the systemic management of psoriasis: International Consensus Conferenceen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum***** University of Michigan Medical School, Ann Arbor, MI, U.S.A.en_US
dc.contributor.affiliationother* St John's Institute of Dermatology, St Thomas' Hospital, London, UKen_US
dc.contributor.affiliationother† Johann Wolfgang Goethe-University, Frankfurt am Main, Germanyen_US
dc.contributor.affiliationother† Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlandsen_US
dc.contributor.affiliationother§ Clinica Dermatologica, UniversitÀ degli Studi di Roma ‘Tor Vergata’, Rome, Italyen_US
dc.contributor.affiliationother¶ University of Kiel, Kiel, Germanyen_US
dc.contributor.affiliationother** University Hospital LiÈge, LiÈge, Belgiumen_US
dc.contributor.affiliationother†† Hospital Universitario Germans Trias i Pujol, Barcelona, Spainen_US
dc.contributor.affiliationother** University of Manchester, Manchester, UKen_US
dc.contributor.affiliationother§§ University of Athens Medical School, Athens, Greeceen_US
dc.contributor.affiliationother¶¶ Aarhus University Hospital, Aarhus, Denmarken_US
dc.contributor.affiliationother*** Lynde Centre for Dermatology, Toronto, Ontario, Canadaen_US
dc.contributor.affiliationother††† Texas Dermatology Research Institute, Dallas, TX, U.S.A.en_US
dc.contributor.affiliationother††† Nice University, Nice, Franceen_US
dc.contributor.affiliationother§§§ University of Western Ontario, London, Ontario, Canadaen_US
dc.contributor.affiliationother¶¶¶ University of Munich, Munich, Germanyen_US
dc.contributor.affiliationother**** Department of Dermatology, The National Hospital, Oslo, Norwayen_US
dc.contributor.affiliationother†††† HÔpital Cantonal Universitaire, Geneva, Switzerlanden_US
dc.contributor.affiliationother†††† Karolinska University Hospital, Solna, Stockholm, Swedenen_US
dc.contributor.affiliationother§§§§ University Institute Cemic Dermatology, Buenos Aires, Argentinaen_US
dc.contributor.affiliationother¶¶¶¶ University Hospital Nijmegen, Nijmegen, the Netherlandsen_US
dc.identifier.pmid15265063en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72815/1/j.1365-2133.2004.06070.x.pdf
dc.identifier.doi10.1111/j.1365-2133.2004.06070.xen_US
dc.identifier.sourceBritish Journal of Dermatologyen_US
dc.identifier.citedreferenceWeinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis 2003; 72: 396 – 8.en_US
dc.identifier.citedreferenceZanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol 2003; 49: S78 – 86.en_US
dc.identifier.citedreferenceGriffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1 – 125.en_US
dc.identifier.citedreferencePrinz J. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 257 – 70.en_US
dc.identifier.citedreferencede Arruda LH, De Moracs AP. The impact of psoriasis on quality of life. Br J Dermatol 2001; 144 ( Suppl. 58 ): 33 – 6.en_US
dc.identifier.citedreferenceRapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401 – 7.en_US
dc.identifier.citedreferenceAshcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000; 25: 1 – 10.en_US
dc.identifier.citedreferenceTristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998; 61: 11 – 21.en_US
dc.identifier.citedreferenceBoehncke WH. Immunomodulatory drugs for psoriasis. Br Med J 2003; 327: 634 – 5.en_US
dc.identifier.citedreferenceMrowietz U. Advances in systemic therapy for psoriasis. Clin Exp Dermatol 2001; 26: 362 – 7.en_US
dc.identifier.citedreferenceBos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40 – 6.en_US
dc.identifier.citedreferenceGriffiths CE. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol 2003; 17 ( Suppl. 2 ): 1 – 5.en_US
dc.identifier.citedreferenceKrueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1 – 23.en_US
dc.identifier.citedreferenceNickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104 – 10.en_US
dc.identifier.citedreferenceGottlieb AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002; 105: 105 – 16.en_US
dc.identifier.citedreferenceSingri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002; 138: 657 – 63.en_US
dc.identifier.citedreferenceKirby B, Griffiths CE. Novel immune-based therapies for psoriasis. Br J Dermatol 2002; 146: 546 – 51.en_US
dc.identifier.citedreferenceDubertret L. Strategy for treatment of psoriasis: systemic treatments. J Dermatol 1998; 25: 788 – 92.en_US
dc.identifier.citedreferenceKrueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280 – 4.en_US
dc.identifier.citedreferenceSalonen SH. The EUROPSO psoriasis patient study. treatment history and satisfaction reported by 17,990 members of European psoriasis patient associations. Poster presented at the Spring Symposium of the European Academy of Dermatology and Venereology, 27 February−1 March 2003, Malta.en_US
dc.identifier.citedreferenceNaldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977–2000: the EDEN survey. J Invest Dermatol 2003; 120: 738 – 41.en_US
dc.identifier.citedreferenceSpuls PI, Witkamp L, Bossuyt PM, et al. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 137: 943 – 9.en_US
dc.identifier.citedreferenceRoenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478 – 85.en_US
dc.identifier.citedreferenceLebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39: 464 – 75.en_US
dc.identifier.citedreferenceFinlay AY. Psoriasis from the patient's point of view. Arch Dermatol 2001; 137: 352 – 3.en_US
dc.identifier.citedreferenceKoo JY. Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol 1999; 26: 723 – 33.en_US
dc.identifier.citedreferenceMenter MA, Abramovits W. Rational, sequential and combination regimens in the treatment of psoriasis. Dermatol Ther 1999; 11: 88 – 95.en_US
dc.identifier.citedreferenceRoenigk HH Jr. Combination and rotational therapy for psoriasis. In: Psoriasis ( Hrah M, ed.), 3rd edn. New York: Marcel Dekker, 1998: 587 – 92.en_US
dc.identifier.citedreferencevan de Kerkhof PC. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 2001: 26: 356 – 61.en_US
dc.identifier.citedreferenceWeinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454 – 9.en_US
dc.identifier.citedreferenceYamauchi PS, Rizk D, Kormeili T, et al. Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 2003; 49: S66 – 77.en_US
dc.identifier.citedreferenceLampen A, Christians U, Bader A, et al. Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 1996; 52: 159 – 68.en_US
dc.identifier.citedreferenceLi AP, Maurel P, Gornez-Lechon MJ, et al. Preclinical evaluation of drug–drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 1997; 107: 5 – 16.en_US
dc.identifier.citedreferenceLebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487 – 98.en_US
dc.identifier.citedreferenceGrossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31: 68 – 74.en_US
dc.identifier.citedreferencePaul BS, Momtaz K, Stern RS, et al. Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 7: 758 – 62.en_US
dc.identifier.citedreferenceSaurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988; 177: 218 – 24.en_US
dc.identifier.citedreferenceChoi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49: S57 – 61.en_US
dc.identifier.citedreferenceHeydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658 – 65.en_US
dc.identifier.citedreferenceChaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842 – 7.en_US
dc.identifier.citedreferenceLebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719 – 27.en_US
dc.identifier.citedreferenceLebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004 – 13.en_US
dc.identifier.citedreferenceLeonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014 – 22.en_US
dc.identifier.citedreferenceGottlieb AB, Gordon KB, Caro I, et al. Long-term efalizumab therapy safely maintains psoriasis area and severity index improvement: preliminary results from an open-label trial. Poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004: Washington, DC. Poster 611.en_US
dc.identifier.citedreferenceMenter A, Cather JC. Long-term use of alefacept: safety and off-treatment responses in patients who have received multiple courses of therapy. Poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004: Washington, DC. Poster 608.en_US
dc.identifier.citedreferenceGordon KB, Siegfried E, Carey W, et al. Impact of 24 weeks of continuous efalizumab therapy on patient-reported outcomes in patients with moderate to severe plaque psoriasis. Poster presented at the Meeting of the American Association of Dermatology Academy, 25–29 July 2003: Chicago, IL.en_US
dc.identifier.citedreference45  Genentech Inc. Raptiva™ ( efalizumab ). South San Francisco, CA: Genentech Inc., October 2003 (Package insert).en_US
dc.identifier.citedreferenceCooper JC, Morgan G, Harding S, et al. Alefacept selectively promotes NK cell-mediated deletion of CD45RO+ human T cells. Eur J Immunol 2003; 33: 666 – 75.en_US
dc.identifier.citedreferenceGottlieb AB, Casale TB, Frankel E, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 2003; 49: 816 – 25.en_US
dc.identifier.citedreferenceBaert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601 – 8.en_US
dc.identifier.citedreferenceDebandt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003; 22: 56 – 61.en_US
dc.identifier.citedreferenceVermeire S, Noman M, van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125: 32 – 9.en_US
dc.identifier.citedreferenceKwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807 – 11.en_US
dc.identifier.citedreferenceMohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862 – 9.en_US
dc.identifier.citedreferenceWeinstein GD, Jeffes E, McCullough JL. Cytotoxic and immunologic effects of methotrexate in psoriasis. J Invest Dermatol 1990; 95: S49 – 52.en_US
dc.identifier.citedreferenceBrown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151 – 8.en_US
dc.identifier.citedreferenceGelfand JM, Berlin J, van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003; 139: 1425 – 9.en_US
dc.identifier.citedreferenceGardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148 – 55.en_US
dc.identifier.citedreferenceKeane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098 – 104.en_US
dc.identifier.citedreferenceWolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372 – 9.en_US
dc.identifier.citedreferenceGomez-Reino JJ, Cannona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122 – 7.en_US
dc.identifier.citedreferenceMoreland LW, Cohen SB, Baurngartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238 – 44.en_US
dc.identifier.citedreferenceSchaible TF. Long term safety of infliximab. Can J Gastroenterol 2000; 14 ( Suppl. C ): C29 – 32.en_US
dc.identifier.citedreferenceFeldman SR, Bala M, Menter A, Gordon KB. The quality of life of patients with severe psoriasis treated with infliximab. Poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004: Washington, DC: Poster 7.en_US
dc.identifier.citedreferencePapp KA, Miller B, Lynde C, et al. Efalizumab (anti-CD11a) retreatment: final results from an open-label study. Poster presented at the Meeting of the American Academy of Dermatology, 21–26 March 2003: San Francisco, CA.en_US
dc.identifier.citedreferenceIyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 146: 118 – 21.en_US
dc.identifier.citedreferenceKrueger GG, van de Kerkhof P. Safety of multiple courses of alefacept in combination with other psoriasis therapies: a study that reflects the clinical practice setting. Poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004: Washington, DC. Poster 591.en_US
dc.identifier.citedreferenceGottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627 – 32.en_US
dc.identifier.citedreferenceSpuls Pl, Bossuyt PM, van Everdingen JJ, et al. The development of practice guidelines for the treatment of severe plaque form psoriasis. Arch Dermatol 1998; 134: 1591 – 6.en_US
dc.identifier.citedreferenceCallen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003; 49: 1 – 4.en_US
dc.identifier.citedreferenceGach JE, Berth-Jones J. Successful treatment of recalcitrant psoriasis with a combination of infliximab and hydroxyurea. J Dermatol Treat 2003; 14: 226 – 8.en_US
dc.identifier.citedreferenceElewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002; 47: 796 – 7.en_US
dc.identifier.citedreferenceNewland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002; 41: 449 – 52.en_US
dc.identifier.citedreferenceRongioletti F, Borenstein M, Kirsner R, et al. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatol Treat 2003; 14: 222 – 5.en_US
dc.identifier.citedreferenceSpuls PI, Hadi S, Rivera L, et al. Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatol Treat 2003; 14 ( Suppl. 2 ): 21 – 5.en_US
dc.identifier.citedreferenceWalters IB, Burack LH, Coven TR, et al. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999; 40: 893 – 900.en_US
dc.identifier.citedreferenceCaIzavara-Pinton PG, Carlino A, Manfredi E, et al. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol (Stockh) 1994; 186 ( Suppl. ): 164 – 5.en_US
dc.identifier.citedreferenceLauharanta J. Photochemotherapy. Clin Dermatol 1997; 15: 769 – 80.en_US
dc.identifier.citedreferenceMorison WL, Baughman RD, Day RM, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134: 595 – 8.en_US
dc.identifier.citedreferenceStem RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755 – 61.en_US
dc.identifier.citedreference81  ICN Pharmaceuticals Inc. Oxsoralen-Ultra ® capsules (methoxsalen capsules, USP, 10 mg). Costa Mesa, CA: ICN Pharmaceuticals Inc., 1998 (package insert).en_US
dc.identifier.citedreference82  Novartis Pharmaceutical Corp. Neoral ® soft gelatin capsules (cyclosporin capsules, USP) modified; Neoral ® oral solution (cyclosporin oral solution, USP) modified. East Hanover, NJ: Novartis Pharmaceutical Corp., August 2002 (package insert).en_US
dc.identifier.citedreferenceDe Rie MA, Bos JD. Cyclosporine immunotherapy. Clin Dermatol 1997; 15: 811 – 21.en_US
dc.identifier.citedreferenceGawkrodger M, on behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of Dermatologists. Current management of psoriasis. J Dermatol Treat 1997; 8: 27 – 55.en_US
dc.identifier.citedreferenceLebwohl M. Psoriasis. Lancet 2003; 361: 1197 – 204.en_US
dc.identifier.citedreferenceGrossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132: 623 – 9.en_US
dc.identifier.citedreference87  Lederle Pharmaceutical. Methotrexate sodium tablets, methotrexate sodium for injection, methotrexate LPF ® sodium (methotrexate sodium injection) and methotrexate sodium injection. Pearl River, NY: Lederle Pharmaceutical, August 2001 (package insert).en_US
dc.identifier.citedreferenceSaid S, Jeffes EW, Weinstein GD. Methotrexate. Clin Dermatol 1997; 15: 781 – 97.en_US
dc.identifier.citedreference89  Roche Laboratories Inc. Soriatane ® (acitretin) capsules. Nutley, NJ: Roche Laboratories Inc., 1998 (Package insert).en_US
dc.identifier.citedreferenceMrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Furnaric Acid Ester Consensus Conference. Br J Dermatol 1999; 141: 424 – 9.en_US
dc.identifier.citedreferenceMrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with furnatic acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998; 138: 456 – 60.en_US
dc.identifier.citedreferenceHoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149: 363 – 9.en_US
dc.identifier.citedreferenceKolbach DN, Nieboer C. Fumaric acid therapy in psoriasis. results and side effects of 2 years of treatment. J Am Acad Dermatol 1992; 27: 769 – 71.en_US
dc.identifier.citedreference94  Biogen Inc. Amevive ® (alefacept). Cambridge, MA: Biogen Inc., 2003 (Package insert).en_US
dc.identifier.citedreferenceOrtonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17 ( Suppl. 2 ): 12 – 6.en_US
dc.identifier.citedreferenceGordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003; 2: 624 – 8.en_US
dc.identifier.citedreferenceEllis CN, Mordin NM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003; 4: 131 – 9.en_US
dc.identifier.citedreferenceGordon KB, Papp KA, Hamilton TK, et al. Efalizuamb for patients with moderate to severe plaque psoriasis: a randomized controlled trial. J Am Med Assoc 2003; 290: 3073 – 80.en_US
dc.identifier.citedreference99  Immunex Corp. Enbrel ® (etanercept). Thousand Oaks, CA: Immunex Corp., 2003 (Package insert).en_US
dc.identifier.citedreference100  Centocor Inc. Remicade ® (infliximab). Malvern, PA: Centocor Inc., 2002 (Package insert).en_US
dc.identifier.citedreferenceGottlieb AB, Chaudhari U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48: 829 – 35.en_US
dc.identifier.citedreferenceGottlieb AB, Chaudhari U, Baker DG, et al. The National Psoriasis Foundation psoriasis score (NPF-PS) system versus the psoriasis area severity index (PASI) and physician's global assessment (PGA): a comparison. J Drugs Dermatol 2003; 3: 260 – 6.en_US
dc.identifier.citedreferenceGottlieb AB, Psoriasis. Dis Manag Clin Outcomes 1998; 1: 195 – 202.en_US
dc.identifier.citedreferencePardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician 2000; 61: 725 – 33.en_US
dc.identifier.citedreferenceKrueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281 – 5.en_US
dc.identifier.citedreferenceBaughman RD, Sobel R. Psoriasis. A measure of severity. Arch Dermatol 1970; 101: 390 – 5.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2133.2004.06070.x.pdf
Size:
163.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.